RecruitingNot ApplicableNCT05436093

CLDN18.2 Targeting Nanobody Probe for PET Imaging in Solid Tumors

Sponsor

Peking University Cancer Hospital & Institute

Enrollment

15 participants

Start Date

Jun 23, 2022

Study Type

INTERVENTIONAL

Conditions

Solid Tumor

Summary

The objective of the study is to construct a noninvasive approach 68Ga-ACN376 PET/CT to detect the CLDN18.2 expression of tumor lesions in patients with Solid tumors and to identify patients benefiting from CLDN18.2 targeting treatment.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Inclusion Criteria4

\. Aged >18 years old; ECOG 0 or 1;
\. Patients with solid tumors;
\. Has at least one measurable target lesion according to Response Evaluation Criteria in Solid Tumors (RECIST V1.1);
\. life expectancy >=12 weeks.

Exclusion Criteria6

\. Significant hepatic or renal dysfunction;
\. Is pregnant or ready to pregnant;
\. Cannot keep their states for half an hour;
\. Refusal to join the clinical study;
\. Suffering from claustrophobia or other mental diseases;
\. Any other situation that researchers think it is not suitable to participate in the experiment.